Chemours Corpus Christi Site Wins 2025 Better Project Award for Innovative Energy and Water Reduction
Project Background and Objectives
Chemours Corpus Christi site produces Opteon™ YF (R-1234yf), a sustainable, non-ozone depleting, low global warming potential refrigerant used in cars, homes, hospitals, and throughout the cold chain. The site is located in Ingleside, Texas, a community currently facing a stage 3 drought. To minimize water and energy use, Chemours initiated a project to return condensed steam (condensate) back to the steam cogeneration operations.
Given the water-stressed conditions in South Texas, this initiative is particularly impactful. The project aimed to ensure the quality of the condensate through advanced analytical equipment and monitoring, enabling safe return to the cogeneration unit and achieving significant financial and energy savings.
Approach and Implementation
The project began with the installation of Total Organic Carbon (TOC) analyzers to monitor condensate return quality. These analyzers provided real-time measurements of condensate quality, validated against manually collected samples. After successful trials, additional transmitters were installed in late 2023, allowing Chemours to significantly increase the amount of condensate returned and ultimately reused.
Since the project launch, the condensate return increased by nearly 40%—from 17.6% to 57.5%—translating to an annual savings of over 70 million gallons of water and $520,000. The initiative also resulted in substantial energy savings, estimated at 134,000 MMBTU/year, a reduction of over 7,000 tonnes of carbon dioxide equivalent (CO2e) annually. The initiative serves as a proof-of-concept that can be replicated across other facilities.
Sustained Impact
Chemours's success at the Corpus Christi site underscores its dedication to environmental stewardship and operational excellence. By leveraging advanced technology and fostering strong partnerships, Chemours is paving the way for a more sustainable future.
For more information about Chemours and its sustainability initiatives, visit chemours.com/sustainability.
Visit 3BL Media to see more multimedia and stories from Chemours
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
CORRECTION – Bringing Advanced Vascular Diagnostics to the Western US with the SmartVascular Dx™ Test
IRVINE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests that addresses unmet clinical needs, announced today corrections to the second paragraph of its press release under the same headline sent out on August 8, 2025. The corrected release follows: MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now available in the Western United States. This innovative diagnostic tool aims to enhance vascular health monitoring in the region. We are also pleased to announce that we are now in-network with Blue Cross Blue Shield of Arizona, allowing us to better serve this market. Additionally, we have secured contracts that enable the reimbursement of claims through United Healthcare, Aetna, Cigna, and Humana on a nationwide basis. These claims will be reimbursed on an out-of-network basis and apply to their PPO and Medicare Advantage plans. We are happy to share that the SmartVascular Dx test is also covered by Medicare. Why SmartVascular Should Be Your Go-To Test The SmartVascular Dx test is essential for the early detection of vascular disease, which is a significant health concern in many communities. Its capabilities enable timely and targeted interventions that can significantly improve health outcomes. Furthermore, we would like to remind our partners that we have collaborated with My One Medical Source® (MOMS), and its network of MAPs: Medical Access Points/Providers™, which will facilitate specimen collection opportunities for MorningStar Laboratories' patients across the country. As the 'Connection for the Collection™,' MOMS enhances access to testing by bridging labs like ours with the skilled personnel needed for specimen collection. For more information and to learn how to integrate the SmartVascular Dx test into your practice, please reach out MorningStar Laboratories at 866.299.8998. Join us in our mission to enhance vascular care and improve the health of our communities. About MorningStar Laboratories MorningStar Laboratories ('MSL') is a specialty diagnostics development clinical laboratory company that develops, performs, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, imaging, and a patented algorithm to address the most challenging clinical problems related to endothelial and vascular inflammatory issues. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit MorningStar Laboratories at Facebook, X (formerly Twitter), and LinkedIn. About My One Medical Source® (MOMs) My One Medical Source® (MOMS) is a SaaS platform connecting labs and other clients with the skilled labor required to perform specimen collections. The MAP: Medical Access Point/Provider™ Network is comprised of both brick-and-mortar draw sites as well as mobile phlebotomy options in all 50 states and Puerto Rico, which serve as collection solutions for the Labs/Clients on the MOMS platform. To learn more, visit Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. Media Contact mjjohnson@ 866.299.8998
Yahoo
5 hours ago
- Yahoo
Ligand to Participate in September Investor Conferences
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 at 1:00 p.m. ET. Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Citi or H.C. Wainwright representative. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit Follow Ligand on X and LinkedIn. We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts. Contacts Investors:Melanie Hermaninvestors@ 550-7761 Media:Kellie Walshmedia@ 315-6072Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
6 hours ago
- Business Wire
Anaergia S.r.l. Announces Agreement to Provide Infrastructure and Equipment for New Biomethane Plants in Spain
TREVIGLIO, Italy & BURLINGTON, Ontario--(BUSINESS WIRE)--Anaergia Inc. ('Anaergia', the 'Company', 'us', or 'our') (TSX:ANRG; OTCQX:ANRGF), through its subsidiary Anaergia S.r.l., has signed a Binding Agreement ('Agreement') with a leading Spanish company specializing in renewable gas infrastructure projects. Under the terms of the Agreement, Anaergia will provide a range of services as well as its cutting-edge technology and equipment for over 15 new biomethane production plants across Spain. Anaergia will be responsible for the supply and construction of concrete tanks with Triton™ digesters, a proprietary technology featuring a patented configuration that significantly enhances process efficiency. In addition, the company will supply advanced mixing systems, also part of its proprietary technology, along with other critical components to facilitate the seamless operations of the plants. Anaergia is to commence activities on the first project this month, with all the projects in the development plan expected to be fully operational and integrated into Spain's gas pipeline network within forty-eight months. Anaergia anticipates total revenue of C$184 million from this Agreement, making it the Company's largest capital sale to date. 'This agreement marks a significant milestone in advancing Spain's renewable energy sector, fostering economic growth and environmental sustainability. The scale of this historic Agreement for Anaergia highlights the advantages of our strategic focus on leveraging proprietary technologies for the benefit of our customers, and underscores our growing presence and activities in Europe,' said Assaf Onn, CEO of Anaergia. 'We are most excited about this opportunity to demonstrate the value of our innovative solutions and to support the global transition to renewable energy.' About Anaergia Anaergia is a pioneering technology company in the renewable natural gas (RNG) sector, with over 250 patents dedicated to converting organic waste into sustainable solutions such as RNG, fertilizer, and water. We are committed to addressing a significant source of greenhouse gases (GHGs) through cost-effective processes. Our proprietary technologies, combined with our engineering expertise and vast experience in facility design, construction, and operation, position Anaergia as a leader in the RNG industry. With a proven track record of delivering hundreds of innovative projects over the past decade, we are well-equipped to tackle today's critical resource recovery challenges through diverse project delivery methods. As one of the few companies worldwide offering an integrated portfolio of end-to-end solutions, we effectively combine solid waste processing, wastewater treatment, organics recovery, high-efficiency anaerobic digestion, and biomethane production. Additionally, we operate RNG facilities owned by both third parties and Anaergia. This comprehensive approach not only reduces environmental impact but also significantly lowers costs associated with waste and wastewater treatment while mitigating GHG emissions. For further information please see: Forward-Looking Statements This news release contains forward-looking information within the meaning of applicable securities legislation, which reflects Anaergia's current expectations regarding future events, including but not limited to, counterparty contractual performance, the capability of the Company's technology and performance with respect to the project objectives. Forward-looking information is based on a number of assumptions, including, but not limited to counterparty contractual performance, the full development, timing and funding of construction of the sixteen facilities, the capability of the Company's technology and performance with respect to the project objectives, the expected revenue from the agreement, and the sufficient sourcing of food waste and power generation. The Company is subject to a number of risks and uncertainties, many of which are beyond the Company's control. Such risks and uncertainties include, but are not limited to, the factors discussed under 'Risk Factors' in the Company's annual information form for the fiscal year ended December 31, 2024, and under 'Risks and Uncertainties' in the Company's most recent management's discussion and analysis. Actual results could differ materially from those projected herein. Anaergia does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws. Additional information on these and other factors that could affect Anaergia's operations or financial results are included in Anaergia's reports on file with Canadian regulatory authorities.
